The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: Most guidelines for major depressive disorder recommend initial treatment with either a second-generation antidepressant (SGA) or cognitive behavioral therapy (CBT). Although most trials suggest that these treatments have similar efficacy, their health economic implications are uncertain. Objective: To quantify the cost-effectiveness of CBT versus SGA for initial treatment of depression. Design: Decision analytic model. Data Sources: Relative effectiveness data from a meta-analysis of randomized controlled trials; additional clinical and economic data from other publications. Target Population: Adults with newly diagnosed major depressive disorder in the United States. Time Horizon: 1 to 5 years. Perspectives: Health care sector and societal. Intervention: Initial treatment with either an SGA or group and individual CBT. Outcome Measures: Costs in 2014 U.S. dollars, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Results of Base-Case Analysis: In model projections, CBT produced higher QALYs (3 days more at 1 year and 20 days more at 5 years) with higher costs at 1 year (health care sector, $900; societal, $1500) but lower costs at 5 years (health care sector, -$1800; societal, -$2500). Results of Sensitivity Analysis: In probabilistic sensitivity analyses, SGA had a 64% to 77% likelihood of having an incremental cost-effectiveness ratio of $100 000 or less per QALY at 1 year; CBT had a 73% to 77% likelihood at 5 years. Uncertainty in the relative risk for relapse of depression contributed the most to overall uncertainty in the optimal treatment. Limitation: Long-term trials comparing CBT and SGA are lacking. Conclusion: Neither SGAs nor CBT provides consistently superior cost-effectiveness relative to the other. Given many patients' preference for psychotherapy over pharmacotherapy, increasing patient access to CBT may be warranted. Primary Funding Source: Department of Veterans Affairs, National Institute of Mental Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 6×
“Each treatment within the model includes 5 health states: initiation (the first month of a given treatment); remission (near-complete recovery of depression, defined by score on a validated symptom rating scale [for example, 16-item Quick Inventory of Depressive Symptomatology ≤5]) (31); response (partial recovery of…”
InfluentialSanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069 · cited 2×
“Future costs and QALYs in the model are discounted at an annual rate of 3% to reflect their present value (24).”
Rudd (2006) · doi:10.1002/(issn)1097-4679 · Cited by 2,635
Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1405158 · Cited by 2,249 · cited 1×
“In the United States, medical interventions with ICERs below $50 000 to $150 000 per QALY may be considered “cost-effective” (27, 28).”
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., & Loder, E. (2013) · Value in Health · doi:10.1016/j.jval.2013.02.002 · Cited by 1,998
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., Addis, M. E., Gallop, R., McGlinchey, J. B., Markley, D. K., Gollan, J. K., et al. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.4.658 · Cited by 1,607
Cost of Lost Productive Work Time Among US Workers With Depression
Stewart, W. F. (2003) · JAMA · doi:10.1001/jama.289.23.3135 · Cited by 1,421 · cited 3×
“4 hours per week for depression in remission, response, and nonresponse states, respectively (42).”
Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989
McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07757 · Cited by 800 · cited 2×
“patients initiating depression treatment per year (63, 64), moving from current (<25%) (9) to patient-preferred (70%) (8) levels of CBT use could thus save more than $1.”
Weinberger, A. H., Gbedemah, M., Martinez, A. M., Nash, D., Galea, S., & Goodwin, R. D. (2018) · Psychological Medicine · doi:10.1017/s0033291717002781 · Cited by 716
Cuijpers, P., Vogelzangs, N., Twisk, J., Kleiboer, A., Li, J., & Penninx, B. W. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030325 · Cited by 677
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580 · cited 1×
“These values were derived from a prospective study of patients treated for MDD (39) and are consistent with utility estimates from clinical trials (52, 53).”
Parikh, S. V., Quilty, L. C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis, V., Kennedy, S. H., Lam, R. W., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659418 · Cited by 562
Dobson, K. S., Hollon, S. D., Dimidjian, S., Schmaling, K. B., Kohlenberg, R. J., Gallop, R. J., Rizvi, S. L., Gollan, J. K., Dunner, D. L., & Jacobson, N. S. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.76.3.468 · Cited by 560 · cited 1×
“A pooled RR estimate is not provided for relapse, so we performed a meta-analysis of the cited studies (34, 35) using the restricted maximum likelihood method employed by Gartlehner and colleagues (7).”
Dunn, A., Grosse, S. D., & Zuvekas, S. H. (2018) · Health Services Research · doi:10.1111/1475-6773.12612 · Cited by 494
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386
Treatment of Adult Depression in the United States
Olfson, M., Blanco, C., & Marcus, S. C. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.5057 · Cited by 352 · cited 2×
“patients initiating depression treatment per year (63, 64), moving from current (<25%) (9) to patient-preferred (70%) (8) levels of CBT use could thus save more than $1.”
National trends in psychotherapy by office-based psychiatrists
Mojtabai, R., & Olfson, M. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.8.962 · Cited by 283 · cited 1×
“Realizing these cost savings would require overcoming barriers, including limited availability and geographic accessibility of psychotherapy providers (10, 65), reimbursement schemes favoring pharmacotherapy over psychotherapy (66, 67), and CBT's high initial cost.”
Qaseem, A., Barry, M. J., Kansagara, D., & for the Clinical Guidelines Committee of the American College of Physicians (2016) · Annals of Internal Medicine · doi:10.7326/m15-2570 · Cited by 279
Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders
Forte, A., Baldessarini, R. J., Tondo, L., Vázquez, G. H., Pompili, M., & Girardi, P. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.02.011 · Cited by 203 · cited 3×
“Although our model's input data does not extend to 5 years, validation against independent long-term results suggests the model remains accurate over this time horizon (25).”
Cuijpers, P., de Beurs, D. P., van Spijker, B. A. J., Berking, M., Andersson, G., & Kerkhof, A. J. F. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.06.025 · Cited by 176 · cited 1×
“On the basis of meta-analyses showing no significant change in suicide risk with antidepressants (50) or psychotherapy (51), we did not model an effect of depression treatment on suicide mortality.”
Sapin (2004) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-2-20 · Cited by 161
The Depression Treatment Cascade in Primary Care: A Public Health Perspective
Pence, B. W., O’Donnell, J. K., & Gaynes, B. N. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0274-y · Cited by 133
Hollinghurst, S., Peters, T. J., Kaur, S., Wiles, N., Lewisand, G., & Kessler, D. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.073080 · Cited by 123 · cited 1×
“Similarly in the United Kingdom, 1 trial found that Internet-based CBT improved outcomes and was cost-effective relative to usual care (19).”
Braun, C., Bschor, T., Franklin, J., & Baethge, C. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442293 · Cited by 103 · cited 1×
“On the basis of meta-analyses showing no significant change in suicide risk with antidepressants (50) or psychotherapy (51), we did not model an effect of depression treatment on suicide mortality.”
Gauthier, G., Guérin, A., Zhdanava, M., Jacobson, W., Nomikos, G., Merikle, E., François, C., & Perez, V. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1385-0 · Cited by 70 · cited 2×
“For comparison, recent studies of Medicaid patients (61) and primarily privately insured patients (62) receiving SGA or other treatment methods yielded annual costs of $11 263 and $9287, respectively.”
Gueorguieva, R., Chekroud, A. M., & Krystal, J. H. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30038-x · Cited by 67
Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F. (2009) · Neuropsychobiology · doi:10.1159/000226611 · Cited by 39 · cited 1×
“Third, we assessed calculating efficacy of treatments after first-line SGA and CBT on the basis of a 19% reduction in odds of response and remission with each successive treatment (57), rather than using STAR*D data (31).”
Hundt, N. E., Barrera, T. L., Mott, J. M., Mignogna, J., Yu, H.-J., Sansgiry, S., Stanley, M. A., & Cully, J. A. (2014) · Psychological Services · doi:10.1037/a0036907 · Cited by 35 · cited 1×
“Realizing these cost savings would require overcoming barriers, including limited availability and geographic accessibility of psychotherapy providers (10, 65), reimbursement schemes favoring pharmacotherapy over psychotherapy (66, 67), and CBT's high initial cost.”
Antidepressant Medication Prescribing Practices for Treatment of Major Depressive Disorder
Treviño, L. A., Ruble, M. W., Treviño, K., Weinstein, L. M., & Gresky, D. P. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201600087 · Cited by 25
Cited by
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
Reinholt, N., Hvenegaard, M., Christensen, A. B., Eskildsen, A., Hjorthøj, C., Poulsen, S., Arendt, M. B., Rosenberg, N. K., Gryesten, J. R., Aharoni, R. N., et al. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000516380 · Cited by 55
Ross, E. L., & Soeteman, D. I. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900625 · Cited by 51
Self-citationKayser, J., Hu, R. X., Rosenscruggs, D., Li, L., & Xiang, X. (2023) · Clinical Gerontologist · doi:10.1080/07317115.2022.2076636 · Cited by 25
Metadata
- Authors
- Ross, E. L., Vijan, S., Miller, E. M., Valenstein, M., & Zivin, K.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-12-03
- Volume
- 171
- Issue
- 11
- Pages
- 785-795
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2982441253
- Cited by
- 50
- References
- 31
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.